Prudent use of beta2-agonists in the treatment of asthma.
The primary disorder in asthma is airway inflammation, which must be managed with anti-inflammatory agents. A review of recent literature highlights conflicting perspectives of the comparative efficacy and safety of short- and long-acting beta2-agonists and their very different roles in asthma therapy.